Spyre Therapeutics (SYRE) News Today $21.29 -1.12 (-5.00%) Closing price 04:00 PM EasternExtended Trading$21.32 +0.03 (+0.12%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Spyre Therapeutics (NASDAQ:SYRE) Upgraded to "Strong-Buy" at The Goldman Sachs GroupThe Goldman Sachs Group upgraded shares of Spyre Therapeutics to a "strong-buy" rating in a research report on Tuesday.February 21 at 5:50 AM | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Rating Increased to Strong-Buy at The Goldman Sachs GroupFebruary 21 at 1:35 AM | americanbankingnews.comAnalysts Set Spyre Therapeutics, Inc. (NASDAQ:SYRE) PT at $54.83February 20 at 1:15 AM | americanbankingnews.comSpyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis OrganisationFebruary 19 at 8:00 AM | prnewswire.comSpyre Therapeutics initiated with early-stage designation at Goldman SachsFebruary 18 at 8:36 AM | markets.businessinsider.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Recommendation of "Buy" by AnalystsSpyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) has received a consensus rating of "Buy" from the seven brokerages that are currently covering the company, Marketbeat reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 12-month price objecFebruary 17, 2025 | marketbeat.comInvestingPro Fair Value analysis proves accurate on Spyre Therapeutics callFebruary 10, 2025 | msn.comSpyre Therapeutics Announces Grants of Inducement AwardsFebruary 7, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYREFebruary 4, 2025 | prnewswire.comChina Universal Asset Management Co. Ltd. Acquires New Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)China Universal Asset Management Co. Ltd. bought a new position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 12,440 shares of the company's stock, valued at approximately $2February 3, 2025 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYREJanuary 28, 2025 | prnewswire.comAssenagon Asset Management S.A. Has $527,000 Stock Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Assenagon Asset Management S.A. decreased its holdings in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 98.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 22,652 shares of the comJanuary 26, 2025 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Given Average Recommendation of "Buy" by BrokeragesShares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) have earned an average recommendation of "Buy" from the seven ratings firms that are covering the firm, MarketBeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 12-monJanuary 23, 2025 | marketbeat.comPromising Expansion in Rheumatoid Arthritis Drives Buy Rating for Spyre TherapeuticsJanuary 22, 2025 | markets.businessinsider.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYREJanuary 21, 2025 | prnewswire.comSpyre Therapeutics (NASDAQ:SYRE) Shares Up 9.4% - Time to Buy?Spyre Therapeutics (NASDAQ:SYRE) Trading 9.4% Higher - Should You Buy?January 21, 2025 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Stock Price Down 5.3% - What's Next?Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 5.3% - Should You Sell?January 16, 2025 | marketbeat.comFY2024 EPS Forecast for Spyre Therapeutics Lifted by AnalystSpyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) - Stock analysts at Lifesci Capital increased their FY2024 earnings per share (EPS) estimates for shares of Spyre Therapeutics in a note issued to investors on Tuesday, January 14th. Lifesci Capital analyst S. Slutsky now anticipates that the cJanuary 16, 2025 | marketbeat.comInvestors Look Toward Key Inflation Data as US Futures Trend Higher in PremarketJanuary 15, 2025 | msn.comPromising Strategic Advancements and Market Potential Position Spyre Therapeutics for SuccessJanuary 14, 2025 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on Spyre Therapeutics (SYRE)January 14, 2025 | markets.businessinsider.comSpyre Therapeutics (NASDAQ:SYRE) Given "Outperform" Rating at WedbushWedbush reissued an "outperform" rating and issued a $65.00 price objective on shares of Spyre Therapeutics in a research note on Monday.January 13, 2025 | marketbeat.comSpyre Therapeutics, Inc.: Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical ReadoutsJanuary 13, 2025 | finanznachrichten.deSpyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical ReadoutsJanuary 13, 2025 | prnewswire.comSpyre Therapeutics (NASDAQ:SYRE) Trading Down 9.2% - Here's WhySpyre Therapeutics (NASDAQ:SYRE) Trading Down 9.2% - Should You Sell?January 10, 2025 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYREJanuary 8, 2025 | prnewswire.comSpyre Therapeutics (NASDAQ:SYRE) Sees Unusually-High Trading Volume - Here's What HappenedSpyre Therapeutics (NASDAQ:SYRE) Sees Large Volume Increase - Here's WhyJanuary 7, 2025 | marketbeat.comSpyre Therapeutics Announces Grants of Inducement AwardsJanuary 3, 2025 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYREJanuary 2, 2025 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYREDecember 27, 2024 | prnewswire.comGeode Capital Management LLC Has $26.21 Million Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Geode Capital Management LLC lifted its position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 16.4% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 891,048 shares of the company's stockDecember 27, 2024 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Stock Price Down 2.5% - Here's WhySpyre Therapeutics (NASDAQ:SYRE) Stock Price Down 2.5% - What's Next?December 24, 2024 | marketbeat.comBarclays PLC Buys 41,424 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)Barclays PLC grew its stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 64.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 105,467 shares of the company's stock afterDecember 24, 2024 | marketbeat.comState Street Corp Boosts Stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE)State Street Corp lifted its stake in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 9.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,541,555 shares of the company's stock after buying an additional 131December 20, 2024 | marketbeat.comBuy Rating on Spyre Therapeutics: Promising Phase 2 Results and Innovative IBD Treatment StrategiesDecember 18, 2024 | markets.businessinsider.comSpyre Therapeutics to be added to Nasdaq Biotechnology Index at open on 12/23December 18, 2024 | markets.businessinsider.comSpyre Therapeutics Added to the Nasdaq Biotechnology IndexDecember 18, 2024 | prnewswire.comPromising Potential of Spyre Therapeutics’ SPY002 Drives Buy Rating Amid Robust Anti-TL1A MarketDecember 17, 2024 | markets.businessinsider.comSpyre Therapeutics: Different Name, Same TuneDecember 12, 2024 | seekingalpha.comWellington Management Group LLP Raises Holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Wellington Management Group LLP lifted its position in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 89.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,507,200 shares of the company'December 12, 2024 | marketbeat.comJones Trading Initiates Coverage of Spyre Therapeutics (SYRE) with Hold RecommendationDecember 11, 2024 | msn.comSpyre Therapeutics (NASDAQ:SYRE) Stock, Short Interest ReportDecember 10, 2024 | benzinga.comCharles Schwab Investment Management Inc. Purchases 235,094 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)Charles Schwab Investment Management Inc. increased its stake in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 239.4% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 333,275 shares of the coDecember 10, 2024 | marketbeat.comJanus Henderson Group PLC Increases Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Janus Henderson Group PLC boosted its stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 66.3% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,120,531 shares of the company'sDecember 7, 2024 | marketbeat.comCinctive Capital Management LP Takes $1.80 Million Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)Cinctive Capital Management LP acquired a new position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 61,256 shaDecember 4, 2024 | marketbeat.comSpyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Rating of "Buy" from BrokeragesSpyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) has been assigned an average recommendation of "Buy" from the eight brokerages that are currently covering the firm, Marketbeat reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 1 year pricDecember 4, 2024 | marketbeat.comSPYRE ALERT: Bragar Eagel & Squire, P.C. is Investigating Spyre Therapeutics, Inc. on Behalf of Spyre Stockholders and Encourages Investors to Contact the FirmDecember 3, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Spyre Therapeutics, Inc. - SYREDecember 3, 2024 | prnewswire.comSpyre Therapeutics begins dosing subjects in Phase I trials of anti-TL1A antibodiesDecember 3, 2024 | msn.comFmr LLC Acquires 115,898 Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE)Fmr LLC grew its holdings in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 1.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,623,881 shares of the company's stock after buying an addiDecember 3, 2024 | marketbeat.com Get Spyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address SYRE Media Mentions By Week SYRE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SYRE News Sentiment▼0.610.60▲Average Medical News Sentiment SYRE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SYRE Articles This Week▼73▲SYRE Articles Average Week Get Spyre Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies KRYS News Today SWTX News Today BHVN News Today RXRX News Today PTCT News Today OGN News Today RARE News Today ALVO News Today RNA News Today ADMA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SYRE) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SYRE Stock Alerts